Positive and negative aspects of the human immunodeficiency virus protease: Development of inhibitors versus its role in AIDS pathogenesis

Microbiology and Molecular Biology Reviews

Volumn 64, Issue 4, 2000, Pages 725-745

  Ikuta, Kazuyoshi ^a,b   Suzuki, Satoko ^b   Horikoshi, Haruko ^a   Mukai, Tetsu ^a   Luftig, Ronald B ^c  

^a OSAKA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 77003; AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PEPTIDOGLYCAN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; CELL SURFACE; DENDRITIC CELL; HUMAN IMMUNODEFICIENCY VIRUS; LIFE CYCLE; LYMPHOCYTE COUNT; NONHUMAN; PATHOGENESIS; RETROVIRUS; REVIEW; VIRUS GENE; X RAY CRYSTALLOGRAPHY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CLINICAL TRIALS; DRUG DESIGN; DRUG THERAPY; GENES, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 0034444948     PISSN: 10922172     EISSN: None     Source Type: Journal    
DOI: 10.1128/MMBR.64.4.725-745.2000     Document Type: Review

References (386)

1. Ahmad, N., and S. Venkatesan. 1988. Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science 241:1481-1485.
2. Aldrovandi, G., L. Gao, G. Bristos, and J. A. Zack. 1998. Regions of human immunodeficiency virus type 1 nef required for function in vivo. J. Virol. 72: 7032-7039.
3. Alkhatib, G., E. A. Berger, P. M. Murphy, and J. E. Pease. 1997. Determinants of HIV-1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions. J. Biol. Chem. 272:20420-20426.
4. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR-5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
5. Ameisen, J. C., J. Estaquier, T. Idziorek, and F. De Bels. 1995. The relevance of apoptosis to AIDS pathogenesis. Trends Cell Biol. 5:27-32.
6. Archibald, D. W., and G. A. Cole. 1990. In vitro inhibition of HIV-1 infectivity by human salivas. AIDS Res. Hum. Retrovir. 6:1425-1432.
7. Åsjö, B., L. Morfeldt-Manson, J. Albert, G. Biberfeld, A. Karlsson, K. Lidman, and E. M. Fenyö. 1986. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet ii:660-662.
8. Asjö, B., F. Barin, G. Biberfeld, J. Bradac, A. Buve, and S. Dielly. 1997. HIV-subtypes: implications for epidemiology, pathogenicity, vaccines and diagnostics. Workshop Report from European Community and Joint United National Program on HIV/AIDS. AIDS 11:17-36.
9. + cell in HIV-related diseases, p. 171-184. In G. Janossy, B. Autran, and F. Miedema (ed.), Immunodeficiency in HIV infection and AIDS. S. Karger, Basel, Switzerland.
10. Bahmani, M. K., M. Kameoka, T. Nakaya, K. Fujinaga, Q. Zhong, H. Takahashi, T. Nakano, M. Nakai, S. Ueda, I. M. Jones, R. B. Luftig, and K. Ikuta. 1997. Production of doughnut-shaped, protease-defective particles from a human T-cell clone carrying a provirus with specific mutations in the env; pol, vpr and nef genes. AIDS Res. Hum. Retrovir. 13:523-526.
11. Bahmani, M. K., M. Kameoka, T. Goto, K. Sano, R. B. Luftig, and K. Ikuta. 2000. Fusion of uninfected T-cells occurs with immature HIV-1 protease-mutant, but not morphologically similar protease inhibitor derived particles. Virus Res. 66:131-137.
12. Baldwin, E. T., T. H. Bhat, S. Gulnik, B. Liu, I. A. Topol, Y. Kiso, T. Mimoto, H. Mitsuya, and J. W. Erickson. 1995. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure 3:581-590.
13. Banda, N. K., J. Bernier, D. K. Kurahara, R. Kurrle, N. Haigwood, R. P. Sekaly, and T. H. Finkel. 1992. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J. Exp. Med. 176:1099-1106.
14. Barkai, N., M. D. Rose, and N. S. Wingreen. 1998. Protease helps yeast find mating partner. Nature 396:422-423.
15. Barrie, K. A., E. E. Perez, S. L. Lamers, W. G. Farmerie, B. M. Dunn, J. W. Sleasman, and M. M. Goodenow. 1996. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology 219:407-416.
16. Bass, H. Z., W. D. Hardy, R. T. Mitsuyasu, Y. X. Wang, W. Cumberland, and J. L. Fahey. 1992. Immune changes in HIV infection: significant correlation and differences in serum markers and lymphoid phenotypic antigens. Clin. Immunol. Immunopathol. 64:63-70.
17. Bass, H. Z., W. D. Hardy, R. T. Mitsuyasu, Y.-X. Wang, W. Cumberland, and J. L. Fahey. 1992. Eleven lymphoid phenotypic markers in HIV infection: selective changes induced by zidovudine treatment. J. Acquir. Immune Defic. Syndr. 5:890-897.
18. Bazan, H. A., G. Alkhatib, C. C. Broder, and E. A. Berger. 1998. Patterns of CCR5, CXCR4. and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates. J. Virol. 72:4485-4491.
19. Bebenek, K., J. Abbotts, S. H. Wilson, and T. A. Kunkel. 1993. Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J. Biol. Chem. 268:10324-10334.
20. Bednarik, D. P., and T. M. Folks. 1992. Mechanisms of HIV-1 latency. AIDS 6:3-16.
21. Bergey, E. J., M.-I. Cho, M.-L. Hammarskjoid, D. Rekosh, M. J. Levine, B. M. Blumberg, and L. G. Epstein. 1993. Aggregation of human immunodeficiency virus type 1 by human salivary secretions. Crit. Rev. Oral Biol. Med. 4:467-474.
22. Berman, P. W. (ed.). 1998. New perspectives on AIDS vaccine development. AIDS Res. Hum. Retrovir. 14:S185-S333.
23. Blankson, J., D. Persaud, and R. F. Siliciano. 1999. Latent reservoirs for HIV. Curr. Opin. Infect. Dis. 12:5-12.
24. Bleul, C. C., M. Farzan, H. Choe, C. Parolin, I. Clark-Lewis, J. Sodroski, and T. A. Springer. 1996. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382:829-832.
25. Bleul, C. C., L. Wu, J. A. Hoxie, T. A. Springer, and C. R. Mackay. 1997. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94:1925-1930.
26. Blumenstein, J. J., R. Luftig, M. Bu, T. D. Copeland, C. J. Michejda, and S. Oroszlan. 1989. Non-peptide inhibitors of HIV-1 proteinases: synthetic analogs of cerulenin. Cold Spring Harbor Banbury Conference on Viral Proteinases as Targets for Chemotherapy. Curr. Commun. Mol. Biol. 1989: 211-214.
27. Blundell, T. L., J. Cooper, S. I. Foundling, D. M. Jones, B. A. Trash, and M. Szelke. 1982. On the rational design of renin inhibitors: X-ray studies of aspartic proteinases complexed with transition-state analogues. Biochemistry 26:5585-5590.
28. Borman, A., S. Paulous, and F. Clavel. 1996. Resistance of HIV-1 to protease inhibitors: selection of resistance mutations in the presence and in the absence of the drug. J. Gen. Virol. 77:419-426.
29. Boucher, C. A. B., J. M. A. Lange, F. Miedema, G. J. Weverling, M. Koot, J. W. Mulder, J. Goudsmit, P. Kellam, B. A. Larder, and M. Tersmette. 1992. HIV-1 biological phenotype and development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 6:1259-1264.
30. Bouras, A., N. Boggetto, Z. Benatalah, E. DeRosny, S. Sicsic, and M. Reboud-Ravaux. 1999. Design synthesis is an evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease determination. J. Med. Chem. 42:957-962.
31. Boyer, P. L., H. O. Gao, and S. H. Hughes. 1998. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at position 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42:447-452.
32. Brady, H. J. M., D. J. Abraham, D. J. Pennington, C. G. Miles, S. Jenkins, and E. A. Dzierzak. 1995. Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice. J. Virol. 69:7622-7629.
33. Bragardo, M., D. Buonfiglio, M. J. Feito, S. Bonissoni, V. Redoglia, J. M. Rajo, S. Ballester, P. Portoles, G. Garbarino, F. Malavasi, and U. Dianzani. 1997. Modulation of lymphocyte interaction with endothelium and homing by HIV-1 gp120. J. Immunol. 159:1619-1627.
34. Bukovsky, A. A., T. Dorfman, A. Weimann, and H. G. Göttlinger. 1997. Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease. J. Virol. 71:1013-1018.
35. Bukrinsky, M. I., T. L. Stanwick, M. P. Dempsey, and M. Stevenson. 1991. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254:423-427.
36. Burton, D. R. 1997. A vaccine for HIV type 1: the antibody perspective. Proc. Natl. Acad. Sci. USA 94:10018-10023.
37. + cell model of chronic infection. J. Virol. 65:4645-4653.
38. + cells. Science 257:383-387.
39. Cao, Y., D. D. Ho, J. Todd, R. Kokka, M. Urdea, J. D. Lifson, M. Piatak, Jr., S. Chen, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res. Hum. Retrovir. 11:353-361.
40. Cauda, R., E. Tacconelli, M. Tubarello, G. Morace, F. DeBernardis, A. Torosantucci, and A. Cassone. 1999. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J. Acquir. Immune Defic. Syndr. 21:20-25.
41. Celentano, D. D., J. Jittiwutikorn, M. J. Hodge, C. Beyrer, and K. E. Nelson. 1998. Epidemiology of HIV-1 infection in opiate users in northern Thailand. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17:73-78.
42. Cella, M., F. Sallusto, and A. Lanzavecchia. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:10-16.
43. gag. J. Acquir. Immune Defic. Syndr. 10:1-7.
44. Chen, Z. W., Z. C. Kou, C. Lekutis, L. Shen, D. Zhou, M. Halloran, J. Li, J. Sodroski, D. Lee-Parritz, and N. L. Letvin. 1995. T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J. Exp. Med. 182:21-31.
45. Cheng-Mayer, C., D. Seto, M. Tateno, and J. A. Levy. 1988. Biologic features of HIV-1 that correlate with virulence in the host. Science 240:80-82.
46. Chirmule, N., S. Than, S. A. Khan, and S. Pahwa. 1995. Human immunodeficiency virus Tat induces functional unresponsiveness in T cells. J. Virol. 69:492-498.
47. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
48. Chun, T.-W., D. Finzi, J. Margolick, K. Chadwich, D. Schwartz, and R. F. Siliciano. 1995. Fate of HIV-1 infected cells in vivo: rates of transition to stable latency. Nat. Med. 1:1284-1290.
49. Chun, T. W., L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, and H. Taylor. 1997. Quantitation of latent tissue reservoirs and total body load in HIV-1 infection. Nature 387:183-188.
50. Clerici, M., A. Sarin, R. L. Coffman, T. A. Wynn, S. P. Blatt, C. W. Hendrix, S. F. Wolf, G. M. Shearer, and P. A. Henkart. 1994. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc. Natl. Acad. Sci. USA 91:11811-11815.
51. Clouse, K. A., D. Powell, I. Washington, G. Poli, K. Strebel, W. Farrar, B. Barstad, J. Kovacs, A. S. Fauci, and T. M. Folks. 1989. Monokine regulation of HIV-1 expression in a chronically infected human T-cell clone. J. Immunol. 142:431-438.
52. Cocchi, F., A. L. DeVico, A. Garzino-Demo, A. Cara, R. C. Gallo, and P. Lusso. 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2:1244-1247.
53. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
54. Coffin, J. M. 1996. Population dynamics of HIV drug resistance, p. 279-303. In D. D. Richman (ed.), Antiviral drug resistance. John Wiley & Sons, Inc., New York, N.Y.
55. Coffin, J. M., S. H. Hughes, and H. E. Varmus. 1998. Retroviruses. Cold Spring Harbor Press, Cold Spring Harbor, NY.
56. Cohen, O. J., A. Kinter, and A. S. Fauci. 1997. Host factors in the pathogenesis of HIV disease. Immunol. Rev. 159:31-48.
57. Cohen, O. J., G. Pantaleo, G. R. Lam, and A. S. Fauci. 1997. Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. Springer Semin. Immunopathol. 18:305-320.
58. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to Indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
59. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Hobbins, E. Roth, M. Shivaprakash, D. L. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
60. Connor, R., K. E. Sheridan, C. Lai, L. Zhang, and D. D. Ho. 1996. Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 70:5306-5311.
61. + T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J. Virol. 67:1772-1777.
62. Connor, R. I., B. T. Korber, B. S. Graham, B. H. Hahn, D. D. Ho, B. D. Walker, A. U. Neumann, S. H. Vermund, J. Mestecky, S. Jackson, E. Fenamore, Y. Cao, F. Gao, S. Kalams, K. J. Kunstman, D. McDonald, N. McWilliams, A. Trkola, J. P. Moore, and S. M. Wolinsky. 1998. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72:1552-1576.
63. Coppenhaver, D. H., P. Sriyuktasuth-Woo, S. Baron, C. E. Barr, and M. N. Qureshi. 1994. Correlation of nonspecific antiviral activity with the ability to isolate infectious HIV-1 from saliva. N. Engl. J. Med. 330:1314-1315.
64. Couture, L. A., and D. T. Stinchcomb. 1996. Antigene therapy: the use of ribozymes to inhibit gene function. Trends Genet. 12:510-515.
65. Croix, D. A., H. Y. Yeh, J. Sedlacek, R. B. Luftig, and P. D. Gottlieb. 1993. A dominant epitope of HIV-1 protease recognized by hamster monoclonal antibodies. J. Acquir. Immune Defic. Syndr. 6:558-566.
66. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096.
67. Curtain, C. C., M. G. Lowe, C. K. Arunagiri, D. W. Mobley, I. G. Macreadie, and A. A. Azad. 1997. Cytotoxic activity of the amino terminal region of HIV-1 Nef protein. AIDS Res. Hum. Retrovir. 13:1213-1220.
68. Deacon, N. J., A. Tsykin, A. Solomon, K. Smith, M. Ludford-Menting, D. J. Hooker, D. A. McPhee, A. L. Greenway, A. Ellett, C. Chatfield, V. A. Lawson, S. Dwyer, D. Dowton, and J. Mills. 1995. Genomic structure of an attenuated quasispecies of HIV-1 from a blood transfusion donor and recipients. Science 270:988-991.
69. Debouck, C. 1992. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retrovir. 8:153-164.
70. DeClerq, E. 1998. New perspectives for the treatment of HIV infections. Collect. Czech. Chem. Commun. 63:449-479.
71. Dedera, D., W. Hu, N. Y. Heyden, and L. Ratner. 1989. Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells. J. Virol. 63:3205-3208.
72. Deeks, S. D., M. Smith, M. Holodny, and J. O. Kahn. 1997. HIV-1 protease inhibitors: a review for clinicians. JAMA 277:145-153.
73. Delezay, O., N. Koch, N. Yahi, D. Hammamache, C. Tourres, and C. Tamalet. 1997. Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithial cell line HT-29. AIDS 11:1311-1318.
74. Delforge, M.-L., C. Liesnard, L. Debaisieux, M. Tchetcheroff, C.-M. Farber, and J.-P. Van Vooren. 1995. In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. AIDS 9:89-101.
75. Delwart, E. L., H. Pan, A. Neumann, and M. Markowitz. 1998. Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. J. Virol. 72:2416-2421.
76. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
77. Denning, P. H., J. L. Jones, and J. W. Ward. 1997. Recent trends in the HIV epidemic in adolescent and young adult gay and bisexual men. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16:374-379.
78. De Panfilis, G., G. C. Manara, C. Ferrari, and C. Torresani. 1998. Simultaneous colloidal gold immunoelectronmicroscopy labeling of CD1a, HLA-DR, and CD4 surface antigens of human epidermal Langerhans cells. J. Investig. Dermatol. 91:547-552.
79. De Ronde, A., B. Klaver, W. Keulen, L. Smit, and J. Goudsmit. 1992. Natural HIV-1 Nef accelerates virus replication in primary human lymphocytes. Virology 188:391-395.
80. Desrosiers, R. C. 1995. Non-human primate models for AIDS vaccines. AIDS 9(Suppl. A):S137-S141.
81. Dettenhofer, M., and X. F. Yu. 1999. Highly purified human immunodeficiency virus reveals a virtual absence of Vif in virions. J. Virol. 73:1460-1467.
82. Dianzani, U., M. Bragardo, D. Buonfilio, V. Redoglia, A. Funaro, P. Portoles, J. Rojo, F. Malavasi, and A. Pileri. 1995. Modulation of CD4 lateral interaction with lymphocyte surface molecules induced by HIV-1 gp120. Eur. J. Immunol. 25:1306-1310.
83. Ding, J., W. J. McGrath, R. M. Sweet, and W. F. Mangel. 1996. Crystal structure of the human adenovirus proteinase with its 11 amino acid cofactor. EMBO J. 15:1778-1783.
84. Dombrowski, A., G. F. Bills, G. Sabnis, L. R. Koupal, R. Meyer, J. G. Ondeyka, R. A. Gicobbe, R. L. Monaghan, and R. B. Lingham. 1992. Inhibition of HIV protease by a novel cytochalasin. J. Antibiot. 45:671-678.
85. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. C. Peiper, M. Parmentier, R. G. Collman, and R. W. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell 85:1149-1158.
86. Doyon, L., F. Poulin, L. Pilote, C. Clouette, D. Thibeault, G. Croteau, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
87. Doyon, L., C. Payant, L. Brakier-Gingras, and D. Lamarre. 1998. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J. Virol. 72:6146-6150.
88. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
89. Dreyer, G. B., J. C. Boehm, P. Chenera, R. L. DesJarlais, and A. M. Hassell. 1993. A symmetric inhibitor binds HIV-1 protease asymmetrically. Biochemistry 32:937-947.
90. Dropulic, B., and K. T. Jeang. 1994. Gene therapy for HIV infection: genetic antiviral strategies and targets for intervention. Hum. Gene Ther. 5: 927-939.
91. Drusano, G. L., and D. S. Stein. 1998. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor Indinavir. Antimicrob. Agents Chemother. 42: 358-361.
92. Edinger, A. L., T. L. Hoffman, M. Sharron, B. Lee, Y. Yi, W. Choe, D. L. Kolson, B. Mitrovic, Y. Zhou, D. Faulds, R. G. Collman, J. Hesselgesser, R. Horuk, and R. W. Doms. 1998. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 72:7934-7940.
93. Edwards, D. R., and G. Murphy. 1998. Proteases - invasion and more. Nature 394:527-528.
94. Embretson, J., M. Zupancic, J. L. Ribas, A. Burke, P. Racz, K. Tenner-Racz, and A. T. Haase. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359-362.
95. Embretson, J., M. Zupancic, J. Beneke, M. Till, S. Wolinsky, J. L. Ribas, A. Burke, and A. T. Haase. 1993. Analysis of human immunodeficiency virus-infected tissues by amplification of in situ hybridization reveals latent and permissive infections at single-cell resolution. Proc. Natl. Acad. Sci. USA 90:357-361.
96. Erickson, J. W. 1995. The not-so-great escape. Nat. Struct. Biol. 2:523-529.
97. Ezzell, C. 1997. Tha monkey's got AIDS: what now for live AIDS vaccine? J. NIH Res. 9:21-22.
98. Fan, Z., X.-L. Huang, L. Zheng, C. Wilson, L. Borowski, J. Liebmann, P. Gupta, J. Margolick, and C. Rinaldo. 1997. Cultured blood dendritic cells retain HIV-1 antigen-presenting capacity for memory CTL during progressive HIV-1 infection. J. Immunol. 159:4973-4982.
99. Farzan, M., H. Choe, K. Martin, L. Marcon, W. Hofmann, G. Karlsson, Y. Sun, P. Barrett, N. Marchand, N. Sullivan, N. Gerard, C. Gerard, and J. Sodroski J. 1997. Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J. Exp. Med. 186:405-411.
100. Fauci, A. S. 1993. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262:1011-1018.
101. Feinberg, M. B., C. Carpenter, A. S. Fauci, L. K. Stanley, O. Cohen, J. G. Bartlett, J. E. Kaplan, and E. Abrutyn. 1998. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of anti-retroviral agents in HIV-infected adults and adolescents. Ann. Intern. Med. 128:1057-1100.
102. Feito, M. J., M. Bragardo, D. Buonfiglio, S. Bonissoni, F. Bottarel, F. Malavasi, and U. Dianzani. 1997. gp120's derived from four syncytium-inducing HIV-1 strains induce different patterns of CD4 association with lymphocyte surface molecules. Int. Immunol. 9:1141-1147.
103. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
104. Fenyö, E. M., L. M. Månson, F. Chiodi, B. Lind, A. von Gegerfelt, J. Albert, E. Olausson, and B. Åsjö. 1988. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J. Virol. 62:4414-4419.
105. Finkel, T. H., G. Tudor-Williams, N. K. Banda, M. F. Cotton, T. Curiel, C. Monks, T. W. Baba, R. M. Ruprecht, and A. Kupfer. 1995. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat. Med. 1:129-134.
106. Fisher, A. G., B. Ensoli, L. Ivanoff, M. Chamberlain, S. Petteway, L. Ratner, R. C. Gallo, and F. Wong-Staal. 1987. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237:888-893.
107. Folks, T., J. Justement, A. Kinter, C. A. Dinarello, and A. S. Fauci. 1987. Cytokine-induced expression of HIV-1 in a chronically infected promonocytic cell line. Science 238:800-802.
108. Foster, S., P. Beverley, and R. Aspinall. 1995. gp120-induced programmed cell death in recently activated T cells without subsequent ligation of the T cell receptor. Eur. J. Immunol. 25:1778-1782.
109. + T cell decline in vivo. Virology 219:87-95.
110. Fouchier, R. A., J. H. Simon, A. B. Jaffe, and M. H. Malim. 1996. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J. Virol. 70:8263-8269.
111. Fox, P. C., A. Wolff, C.-K. Yen, J. C. Atkinson, and B. J. Baum. 1988. Saliva inhibits HIV-1 infectivity. J. Am. Dent. Assoc. 116:635.
112. Frade, J. M. R., M. Llorente, M. Mellado, J. Alcami, J. C. Gutierrez-Ramos, A. Zaballos, G. Real, and C. Martinez-A. 1997. The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection. J. Clin. Investig. 100:497-502.
113. Frankel, S. S., B. M. Wenig, A. P. Burke, P. Mannan, L. D. R. Thompson, S. L. Abbondanzo, A. M. Nelson, M. Pope, and R. M. Steinman. 1996. Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Science 272:115-117.
114. Freidland, G. H., B. R. Salzman, M. F. Rogers, P. A. Kahl, M. L. Lesser, M. M. Meyers, and R. S. Klein. 1986. Lack of household transmission of HTLV-III infection. N. Engl. J. Med. 314:344.
115. Freund, J., R. Kellner, J. Konvalinka, V. Wolber, H.-G. Kräusslich, and H. R. Kalbitzer. 1994. A possible regulation of Nef activity of HIV-1 by the viral protease. Eur. J. Biochem. 223:589-593.
116. Fujinaga, K., Q. Zhong, T. Nakaya, M. Kameoka, T. Meguro, K. Yamada, and K. Ikuta. 1995. Extracellular Nef protein regulates productive HIV-1 infection from latency. J. Immunol. 155:5289-5298.
117. Fujinaga, K., Y. Nakamura, Q. Zhong, T. Nakaya, and K. Ikuta. 1996. Growth dominance of a revertant virus generated during in vitro serial passage of a nef frameshift mutant of HIV-1. Biochem. Biophys. Res. Commun. 229:96-101.
118. Fujinaga, K., T. Nakaya, and K. Ikuta. 1998. Generation of endogenous tumour necrosis factor-α in MOLT-4 cells during the acute replication phase of human immunodeficiency virus type 1 determined the subsequent latent infection. J. Gen. Virol. 79:221-229.
119. Fultz, P. N. 1986. Components of saliva inactivate human immunodeficiency virus. Lancet ii:1215.
120. Gaedigk-Nitschko, K., A. Schon, G. Wachinger, V. Erfle, and B. Kohleisen. 1995. Cleavage of recombinant and cell derived HIV-1 Nef protein by HIV-1 protease. FEBS Lett. 357:275-278.
121. Galetto-Lacour, A., S. Yerly, T. V. Perneger, C. Baumberger, B. Hirschel, L. Perrin, and the Swiss HIV Cohort Study Group. 1996. Prognosis value of viremia in patients with long-standing human immunodeficiency virus infection. J. Infect. Dis. 173:1388-1393.
122. Gaynor, R. 1992. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS 6:347-363.
123. Gazzard, B. G., G. J. Moyle, J. Weber, M. Johnson, J. S. Bingham, R. Bettle, D. Churchill, M. Fisher, G. Griffin, D. Jeffries, K. E. Gormer, C. Lee, A. Pozniak, J. R. Smith, G. Tudor-Williams, and I. Williams. 1997. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 349:1086-1091.
124. Goto, T., M. Nakai, and K. Ikuta. 1998. The life-cycle of human immunodeficiency virus type 1. Micron 29:123-138.
125. Goudsmit, J., A. De Rondo, D. D. Ho, and A. S. Perelson. 1996. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J. Virol. 70:5662-5664.
126. Gougeon, M.-L., S. Garcia, J. Heeney, R. Tschopp, H. Lecoeur, D. Guetard, V. Rame, C. Dauguet, and L. Montagnier. 1993. Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res. Hum. Retrovir. 9:553-563.
127. Gougeon, M.-L., H. Lecoeur, A. Dulioust, M.-G. Enouf, M. Crouvoiser, C. Goujard, T. Debord, and L. Montagnier. 1996. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J. Immunol. 156:3509-3520.
128. Grierson, A. W., R. Nicholson, P. Talbot, A. Webster, and G. Vemp. 1994. The protease of adenovirus serotype 2 requires cysteine residues for both activation and catalysis. J. Gen. Virol. 75:2761-2764.
129. Groenink, M., R. A. M. Fouchier, R. E. Y. de Goede, F. de Wolf, R. A. Gruters, H. T. M. Cuypers, H. G. Huisman, and M. Tersmette. 1991. Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J. Virol. 65:1968-1975.
130. + T cells from human immunodeficiency virus-infected asymptomatic individuals. J. Exp. Med. 175:331-340.
131. Gruber, A., C. Speth, E. Lukasser-Vogl, R. Zangerle, M. Borg-von Zepelin, M. P. Dierich, and R. Würzner. 1999. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 41:227-234.
132. Gulnik, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34: 9282-9287.
133. Guαnthard, H. F., J. K. Wong, C. C. Ignacio, J. C. Guatelli, N. L. Riggs, D. V. Havlir, and D. D. Richman. 1998. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72:2422-2428.
134. Hammes, S. R., E. P. Dixon, M. H. Malim, B. R. Cullen, and W. C. Greene. 1989. Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Proc. Natl. Acad. Sci. USA 86: 9549-9553.
135. Havlir, D. V., I. C. Marschner, M. S. Hirsch, A. C. Collier, P. Tebas, and R. L. Bassett. 1998. Maintenance antiretroviral therapies in HIV infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N. Engl. J. Med. 339:1261-1268.
136. Haynes, B. F. 1996. HIV vaccines: where we are and where we are going. Lancet 348:933-937.
137. Haynes, B. F., G. Pantaleo, and A. S. Fauci. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-328.
138. He, J., Y. Chen, M. Farzan, H. Choe, A. Ohagen, S. Gartner, J. Busciglio. X. Yang, W. Hofmann, W. Newman, C. R. Mackay, J. Sodroski, and D. Gabuzda. 1997. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385:645-649.
139. Heinzinger, N. K., M. I. Bukrinsky, S. A. Haggerry, A. M. Ragland, V. Kewalramani, M.-A. Lee, H. E. Gendelman, L. Ratner, M. Stevenson, and M. Emerman. 1994. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc. Natl. Acad. Sci. USA 91:7311-7315.
140. gag and p17MA. J. Virol. 73:1902-1908.
141. Hill, R. L. 1965. Hydrolysis of proteins. Adv. Protein Chem. 20:37-107.
142. 2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
143. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
144. Ho, D. D. 1998. Toward HIV eradication or remission: the task ahead. Science 280:1866-1868.
145. Hoch, J., S. M. Lang, M. Weeger, C. Stahl-Hennig, C. Coulibaly, U. Dittmer, G. Hunsmann, D. Fuchs, J. Müller, S. Sopper, B. Fleckenstein, and K. T. Überla. 1995. vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J. Virol. 69:4807-4813.
146. Hofmann, B., P. Nishanian, and J. L. Fahey. 1991. Serum increases and lymphoid cell surface losses of IL-2R (CD25) in HIV infection: distinctive parameters of HIV-induced change. Clin. Immunol. Immunopathol. 61: 212-224.
147. + T lymphocytes to a T-tropic and a macrophage (M)-tropic human immunodeficiency virus type 1 is associated with their surface expression of CD38 molecules. Virus Res., in press.
148. Horuk, R., J. Hesselgesser, Y. Zhou, D. Faulds, M. Halks-Miller, S. Harvey, D. Taub, M. Samson, M. Parmentier, J. Rucker, B. J. Doranz, and R. W. Doms. 1998. The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J. Biol. Chem. 273:386-391.
149. Houghton, M. 1996. Hepatitis C viruses, p. 1035-1058. In B. N. Fields, D. M. Knipe, and P. M. Howey (ed.), Fields virology, 3rd ed. Lippincott-Raven. Philadelphia, Pa.
150. Höver, B., R. L. Sherman, and P. Traub. 1992. Degradation of cytoskeletal proteins by the HIV-1 protease. Cell Biol. Int. Rep. 16:603-612.
151. Huang, Y., L. Zhang, and D. D. Ho. 1995. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 69:93-100.
152. Huang, Y., L. Zhang, and D. D. Ho. 1995. Functional analysis of nef alleles derived from long-term survivors. J. Virol. 69:8142-8146.
153. Humphrey, R. W., A. Öhagen, D. A. Davis, T. Fukazawa, H. Hayashi, S. Hoglung, H. Mitsuya, and R. Yarchoan. 1997. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1
154. Ikuta, K., C. Morita, M. Nakai, N. Yamamoto, and S. Kato. 1988. Defective human immunodeficiency virus (HIV) particles produced by cloned cells of HTLV-1-carrying MT-4 cells persistently infected with HIV. Jpn. J. Cancer Res. 79:418-423.
155. Ikuta K., and R. B. Luftig. 1986. Inhibition of cleavage of Moloney murine leukemia virus gag and env coded precursor polypeptides by cerulenin. Virology 154:195-206.
156. Ikuta, K., M. Kameoka, and R. B. Luftig. 1997. AIDS pathogenesis: the role of accessory gene mutations, leading to formation of long-term persistently infected cells and/ or apoptosis-inducing HIV-1 particles. Virus Res. 52: 145-156.
157. Iversen, A. K. N., E. G. Shpaer, A. G. Rodrigo, M. S. Hirsch, B. D. Walker, H. W. Sheppard, R. C. Merigan, and J. I. Mullins. 1995. Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individuals. J. Virol. 69:5743-5753.
158. Janossy, G., N. Borthwick, and R. Lomnitzer. 1992. Proliferative defects of CD4 and CDS lymphocytes in HIV-1 infection, p. 96-114. In G. Janossy, B. Autran, and F. Miedema (ed.), Immunodeficiency in HIV infection and AIDS. S. Karger. Basel, Switzerland.
159. + T lymphocytes in HIV infection, p. 195-210. In G. Janossy, B. Autran, and F. Miedema (ed.), Immunodeficiency in HIV infection and AIDS. S. Karger, Basel, Switzerland.
160. Jassoy, C., and B. D. Walker. 1997. HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Springer Semin. Immunopathol. 18: 341-354.
161. Ji, J., and L. A. Loeb. 1994. Fidelity of HIV-1 reverse transcriptase copying a hypervariable region of the HIV- 1 env gene. Virology 199:323-330.
162. + T cells, and AIDS. J. Virol. 71:4016-4023.
163. Jones, I., and D. Stuart. 1996. Journey to the core of HIV. Nat. Struct. Biol. 3:818-820.
164. Kacani, L., I. Frank, M. Spruth, M. G. Schwendinger, B. Mullauer, G. M. Sprinzl, F. Steindl, and M. P. Dierich. 1998. Dendritic cells transmit human immunodeficiency virus type 1 to monocytes and monocyte-derived macrophages. J. Virol. 72:6671-6677.
165. Kameoka, M., T. Kimura, Y.-H. Zheng, S. Suzuki, K. Fujinaga, R. B. Luftig, and K. Ikuta. 1997. Proteasc-defective. gp120-containing human immunodeficiency virus type 1 particles induce apoptosis more efficiently than does wild-type virus or recombinant gp120 protein in healthy donor-derived peripheral blood T cells. J. Clin. Microbiol. 35:41-47.
166. + killer cells in a small subset, leading to induction of apoptosis in bystander cells. Int. Immunol. 9:1453-1462.
167. - markers derived from HIV-1 carriers induces apoptosis in healthy donor-derived T-lymphocytes. Virus Res. 56:115-122.
168. Kaplan, A., S. Michael, E. Wehbie, M. Knigge, D. Paul, L. Everitt, D. Kempf, D. Norbeck, J. Erickson, and R. Swanstrom. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA 91:5597-5601.
169. Kaplan, A. H., P. Krogstad, D. J. Kempf, D. W. Norbeck, and R. Swanstrom. 1994. Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of efficiently reverse transcribing viral genomic RNA. Antimicrob. Agents Chemother. 38:2929-2933.
170. Kaplan, D., and S. Sieg. 1998. Role of the Fas/FasL ligand apoptotic pathway in human immunodeficiency virus type 1 disease. J. Virol. 72:6279-6282.
171. Karlsson, A., K. Parsmyr, K. Aperia, E. Sandstrom, E. M. Fenyö, and J. Albert. 1994. MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. J. Infect. Dis. 170:1367-1375.
172. Karlsson, A., K. Parsmyr, E. Sandstrom, E. M. Fenyö, and J. Albert. 1994. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J. Clin. Microbiol. 32:364-370.
173. Katoh, I., T. Yasunaga, Y. Ikawa, and Y. Yoshinaka. 1987. Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor. Nature 329: 654-657.
174. Katoh, Y., Y. Yoshinaka, and R. B. Luftig. 1986. The effect of cerulinen on Moloney murine leukemia virus morphogenesis. Virus Res. 5:265-276.
175. Katsikis, P. D., E. S. Wunderlich, C. A. Smith, L. Herzenberg, and L. A. Herzenberg. 1995. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J. Exp. Med. 181:2029-2036.
176. Katz, R. A., and A. M. Skalka. 1994. The retroviral enzymes. Annu. Rev. Biochem. 63:133-173.
177. Katzenstein, D. A., S. M. Hammer, M. D. Hughers, H. Gundacker, J. B. Jackson, S. Fiscus, S. Rasheed, T. Elbeik, R. Reichman, A. J. Japour, T. C. Merigan, M. S. Hirsch, and AIDS Clinical Trials Group 175 Virology Study Team. 1996. The relation of virologie and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. 335:1091-1098.
178. Kelleher, A. D., A. Carr, J. Zaunders, and D. A. Cooper. 1996. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J. Infect. Dis. 173:321-329.
179. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
180. Kestens, L., G. Vanham, P. Gigase, G. Young, I. Hannet, F. Vanlangendonck, F. Hulstaert, and B. A. Back. 1992. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS 6:793-797.
181. + T lymphocytes during HIV-1 infection. Clin. Exp. Immunol. 95:436-441.
182. Kestler, H. W., D. J. Ringler, K. Mori, D. Panicali, P. K. Sehgal, M. D. Daniel, and R. D. Desrosiers. 1991. Importance of the nef gene for maintenance of high virus loads and/ or development of AIDS. Cell 65:651-662.
183. Kim, S. Y., K. Ikeuchi, R. Byrn, J. Groopman, and D. Baltimore. 1989. Lack of a negative influence of viral growth by the nef gene of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86:9544-9548.
184. Kirchhoff, F., T. C. Greenough, D. B. Brettler, J. L. Sullivan, and R. C. Desrosiers. 1995. Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332:228-232.
185. Kishi, M., Y. Nishino, M. Sumiya, K. Ohki, T. Kimura, T. Goto, M. Nakai, M. Kakinuma, and K. Ikuta. 1992. Cells surviving infection by human immunodeficiency virus type 1 (HIV-1): vif or vpu mutants produce non-infectious or markedly less cytopathic viruses. J. Gen. Virol. 73:77-87.
186. Kishi, M., Y. Nishino, K. Ohki, T. Kimura, and K. Ikuta. 1993. Persistently human immunodeficiency virus type 1-infected T cell clone expressing only doubly spliced mRNA exhibits reduced cell surface CD4 expression. Jpn. J. Cancer Res. 84:153-162.
187. Kishi, M., K. Tokunaga, Y.-H. Zheng, M. K. Bahmani, M. Kakinuma, M. Nonoyama, P. K. Lai, and K. Ikuta. 1995. Superinfection of a defective human immunodeficiency virus type-1 provirus-carrying T cell clone with vif or vpu mutants gives cytopathic virus particles by homologous recombination. AIDS Res. Hum. Retrovir. 11:45-53.
188. Kishi, M., Y.-H. Zheng, M. K. Bahmani, K. Tokunaga, H. Takahashi, M. Kakinuma, P. K. Lai, M. Nonoyama, R. B. Luftig, and K. Ikuta. 1995. Naturally occurring accessory gene mutations lead to persistent human immunodeficiency virus type 1 infection of CD4-positive T cells. J. Virol. 69:7507-7518.
189. Klein, R. S., J. A. Phelan, P. H. Freeman, M. S. Schable, G. H. Friedland, N. Trieger, and N. H. Steigbigel. 1988. Low occupational risk of human immunodeficiency virus infection among dental professionals. N. Engl. J. Med. 318:86.
190. Klimkait, T., K. Strebel, M. D. Hoggan, M. A. Martin, and J. M. Orenstein. 1990. The human immunodeficiency virus type 1-specific protein Vpu is required for efficient virus maturation and release. J. Virol. 64:621-629.
191. Koch, G., and D. Richter (ed.). 1980. Biosynthesis, modification and processing of cellular and viral proteins. Academic Press, Inc., New York, N. Y.
192. Kohl, N. E., E. A. Emini, W. A. Schlief, L. J. Davis, J. C. Heimback, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
193. Koot, M., A. H. V. Vos, R. P. M. Keet, R. E. Y. De Goede, W. Dercksen, F. G. Terpstra, R. A. Coutinho, F. Miedema, and M. Tersmette. 1992. HIV-1 biological phenotype in long term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS 6:49-54.
194. + cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-688.
195. Koot, M., P. T. A. Schellekens, J. W. Mulder, J. M. A. Lange, M. T. L. Roos, R. A. Coutinho, M. Tersmette, and F. Miedema. 1993. Viral phenotype and T-cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. J. Infect. Dis. 168:733-736.
196. Koot, M., A. B. van 'tWout, N. A. Kootstra, R. E. Y. De Goede, M. Tersmette, and H. Schuitemaker. 1996. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 173:349-354.
197. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
198. Kozal, M., N. Shah, N. Shen, R. Yang, R. Fucini, T. Merigan, D. Richman, D. Morris, E. Hubbel, M. Chee, and T. Gingeras. 1996. Extensive polymorphisms observed in HIV-1 clade B protease genes using high-density oligonucleotide arrays. Nat. Med. 2:753-759.
199. Kramps, J. A., C. Franken, and J. G. Dijkman. 1984. ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in human sputum. Am. Rev. Respir. Dis. 129:959-962.
200. Kräusslich, H. G., and E. Wimmer. 1988. Viral proteinases. Annu. Rev. Biochem. 57:701-754.
201. La Casse, R. A., K. E. Follis, M. Trahey, J. D. Scarborough, D. R. Littman, and J. H. Nunberg. 1999. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 283:357-362.
202. Lang, S. M., M. Weeger, C. Stahl-Hennig, C. Coulibaly, G. Hunsmann, J. Muller, H. Muller-Hermelink, D. Fuchs, H. Wachter, M. M. Daniel, R. C. Desrosiers, and B. Fleckenstein. 1993. Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 67:902-912.
203. Lanza, P., R. B. Moss, W. Giermakowska, R. B. Hancock, S. P. Richieri, G. Theofa, F. C. Jensen, P. L. Salk, and D. J. Carlo. 1998. Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination. Vaccine 16:727-731.
204. Learmont, J., B. Tindall, L. Evans, A. Cunningham, P. Cunningham, J. Wells, R. Penny, J. Kaldor, and D. A. Cooper. 1992. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 340:863-867.
205. Lech, W., G. Wang, Y. Yang, Y. Chee, K. Dorman, D. McCrae, L. Lazzeroni, J. Erickson, J. Sinsheimer, and A. Kaplan. 1996. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70:2038-2043.
206. Lee, T. G., and S. Maruyama. 1998. Isolation of HIV-1 protease inhibiting peptides from thermolysin hydrolysate of oyster proteins. Biochem. Biophys. Res. Commun. 253:604-608.
207. Le Grice, S. F. J., J. Mills, and J. Mous. 1988. Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation. EMBO J. 7:2547-2553.
208. Leis, J., I. Weber, A. Wlodawer, and A. M. Skalka. 1990. Structure-function analysis of the Rous sarcoma virus-specific proteinase. ASM News 56:77-81.
209. Letvin, N. L. 1998. Progress in the development of an HIV-1 vaccine. Science 280:1875-1880.
210. Levy, D. N., Y. Refaeli, R. R. MacGregor, and D. B. Weiner. 1994. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 91:10873-10877.
211. Levy, D. N., Y. Refaeli, and D. B. Weiner. 1995. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J. Virol. 69:1243-1252.
212. Levy, J. A. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 57:183-289.
213. + T cells from HIV-infected persons. J. Immunol. 153:412-420.
214. Li, C. J., D. J. Friedman, C. Wang, V. Metelev, and A. B. Pardee. 1995. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 268:429-431.
215. + cells for HIV-exposed infants: preclinical studies. Gene Ther. 5:233-239.
216. Liao, F., G. Alkhatib, K. W. Peden, G. Sharma, E. A. Berger, and J. M. Farber. 1997. STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J. Exp. Med. 185:2015-2023.
217. ™ in HIV-infected Thai subjects. Vaccine 16:142-149.
218. Lin, Y., X. Lin, L. Hong, S. Foundling, R. L. Heinrickson, S. Thaisrivongs, W. Leelamanit, D. Raterman, M. Shah, B. M. Dunn, and J. Tang. 1995. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry 34:1143-1152.
219. Lipsky, J. J. 1998. Abnormal fat accumulation in patients with HIV-1 infection. Lancet 351:847-848.
220. Loeb, D. D., R. Swanstrom, L. Everitt, M. Manchester, S. E. Stamper, and C. A. Hutchison. 1989. Complete mutagenesis of the HIV-1 protease. Nature 340:397-400.
221. Loetscher, M., A. Amara, E. Oberlin, N. Brass, D. Legler, P. Loetscher, M. D'Apuzzo, E. Meese, D. Rousset, J. L. Virelizier, M. Baggiolini, F. Arenzana-Seisdedos, and B. Moser. 1997. TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function. Curr. Biol. 7:652-660.
222. Luciw, P. A., C. Cheng-Mayer, and J. A. Levy. 1987. Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication. Proc. Natl. Acad. Sci. USA 84:1434-1438.
223. Luftig, R. B., and K. Ikuta. 1994. Are defective, HIV protease-deficient particles the real culprit in AIDS? ASM News 60:417-419.
224. Luftig, R. B., K. Ikuta, M. Bu, and P. Calkins. 1990. Terminal stages of retroviral morphogenesis, p. 141-148. In L. H. Pearl (ed.), Retroviral proteases: control of maturation and morphogenesis. Macmillan, London. United Kingdom.
225. Luftig, R. B., and L. Lupo. 1994. Viral interactions with the host-cell cytoskeleton: the role of retroviral proteases. Trends Microhiol. 2:178-182.
226. Luftig, R. B., D. Pieniazek, and N. J. Pieniazek. 1990. Update in viral pathogenesis. ASM News 56:366-368.
227. Mahalingam, S., R. G. Collman, M. Patel, C. E. Monken, and A. Srinivasan. 1995. Functional analysis of HIV-1 Vpr: identification of determinants essential for suhcellular localization. Virology 212:331-339.
228. Mahalingam, M., M. Peakman, E. T. Davies, A. Pozniak, T. J. McManus, and D. Vergani. 1993. T cell activation and disease severity in HIV infection. Clin. Exp. Immunol. 93:337-343.
229. Mahalingam, M., A. Pozniak, T. J. McManus, D. Vergani, and M. Peakman. 1995. Cell cycling in HIV infection: analysis of in vivo activated lymphocytes. Clin. Exp. Immunol. 102:481-486.
230. Malamud, D., C. Davis, P. Berthold, E. Roth, and H. Friedman. 1993. Human submandibular saliva aggregates HIV. AIDS Res. Hum. Retrovir. 9:633-637.
231. Maldarelli, F., H. Sato, E. Berthold, J. Orenstein, and M. A. Martin. 1995. Rapid induction of apoptosis by cell-to-cell transmission of human immunodeficiency virus type 1. J. Virol. 69:6457-6465.
232. Manchester, M., L. Everitt, D. D. Loeb, C. A. Hutchison, and R. Swanstrom. 1994. Identification of temperature-sensitive mutants of human immunodeficiency virus type 1 protease through saturation mutagenesis. Amino acid requirements for temperature sensitivity. J. Biol. Chem. 269: 7689-7695.
233. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
234. Mariana, R., K. Kirchhoff, T. C. Greenough, J. L. Sullivan, R. C. Desrosiers, and J. Skowronski. 1996. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J. Virol. 70:7752-7764.
235. Markowitz, M., H. Mo, D. Kempf, D. Norbeck, T. Bhat, J. Erickson, and D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538. a novel protease inhibitor. J. Virol. 69:701-706.
236. + T cells in vitro. Differential induction of apoptosis in these cells. J. Immunol. 152:330-342.
237. Martinez, E., and J. Gatell. 1998. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet 352:821-822.
238. Maschera, B., E. Furfine, and E. D. Blair. 1995. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69:5431-5436.
239. McCune, J. M. 1995. Viral latency in HIV disease. Cell 82:183-188.
240. McNeely, T. B., M. Dealy, U. J. Dripps, J. M. Orenstein, S. P. Elsienberg, and S. M. Wahl. 1995. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Investig. 96:456-464.
241. McNeely, T. B., D. C. Shugars, M. Rosendahl, C. Tucker, S. P. Eisenberg, and S. M. Wahl. 1997. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90:1141-1149.
242. Medina, D. J., P. P. Tung, C. J. Nelson, B. Sathya, D. Casareole, and R. K. Strair. 1998. Characterization and use of a recombinant retroviral system for the analysis of drug resistant HIV. J. Virol. Methods 71:169-176.
243. Mellors, J. W., C. R. Rinaldo, P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasm. Science 272:1167-1170.
244. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern. Med. 126:946-954.
245. Meyaard, L., S. A. Otto, R. R. Jonker, M. J. Mijnster, R. P. M. Keet, and F. Miedema. 1992. Programmed death of T cells in HIV-1 infection. Science 257:217-219.
246. Michael, N. L., T. Mo, A. Merzouki, M. O'Shaughnessy, C. Oster, D. S. Burke, R. R. Redfield, D. L. Birx, and S. A. Cassol. 1995. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J. Virol. 69:1868-1877.
247. Michael, N. L., G. Change, L. A. d'Arcy, P. K. Ehrenberg, R. Mariani, M. P. Busch, D. L. Birx, and D. H. Schwartz. 1995. Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J. Virol. 69:4228-4236.
248. Miller, C. J., P. Vogel, N. J. Alexander, S. Dandekar, A. G. Hendrickx, and P. A. Marx. 1994. Pathology and localization of simian immunodeficiency virus in the reproductive tract of chronically infected male rhesus macaques. Lab. Investig. 70:255-262.
249. Miller, C. J., P. Vogel, N. J. Alexander, S. Sutjipto, A. G. Hendrickx, and P. A. Marx. 1992. Localization of SIV in the genital tract of chronically infected female rhesus macaques. Am. J. Pathol. 141:655-660.
250. Miller, M. D., M. T. Warmerdam, S. S. Ferrell, R. Benitez, and W. C. Greene. 1997. Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity. Virology 234:215-225.
251. Miller, M. D., M. T. Warmerdam, I. Gaston, W. C. Greene, and M. B. Feinberg. 1994. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J. Exp. Med. 179:101-113.
252. Miller, M. J., B. K. Schreider, and B. K. Sathyanarayana. 1989. Structure of a complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution. Science 245:1149-1152.
253. + T cells in vitro and in vivo: association with Fas-mediated apoptosis and modulation by aurintricarboxylic acid. Immunology 87:581-585.
254. Molla, A., D. Kempf, M. Korneyeva, Q. Gao, P. Shipper, H. Mo, M. Markowitz, S. Vasavanonda, T. Chernyavskyi, P. Niu, N. Lyons, A. Hsu, G. Granneman, D. Ho, C. Boucher, J. Leonard, and D. Norbeck. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
255. Moore, B. E., C. M. Flaitz, D. H. Coppenhaver, C. M. Nichols, G. D. Kalmaz, J. D. Bessman, M. W. Cloyd, D. P. Lynch, B. S. Prabhakar, and S. Baron. 1993. HIV recovery from saliva before and after dental treatment: inhibitors may have critical role in viral inactivation. J. Am. Dent. Assoc. 124:67-74.
256. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9(Suppl. A): S117-S136.
257. Moss, R. B., M. R. Wallace, P. Lanza, W. K. Giermakowska, F. C. Jensen, G. Theofan, C. Chamberlin, S. P. Richieri, and D. J. Carlo. 1998. In vitro p24 antigen-stimulated lymphocyte proliferation and β-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp 120-depleted HIV-1 immunogen (Remune). Clin. Diagn. Lab. Immunol. 5:308-312.
258. Moss, R. B., L. Li, W. K. Giermakowska, P. Lanza, J. L. Turner, M. R. Wallace, F. C. Jensen, S. P. Richieri, A. E. Daigle, G. Theofan, and D. J. Carlo. 1998. Tumor necrosis factor a and HIV-specific functional immune responses after immunization with gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (Remune) in HIV-1 seropositive subjects. J. Hum. Virol. 1:77-81.
259. Moutouh, L., J. Corbell, and D. D. Richman. 1996. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc. Natl. Acad. Sci. USA 93:6106-6111.
260. Moyle, G. 1999. HIV infection and AIDS. Curr. Opin. Infect. Dis. 12:1-27.
261. Muro-Cacho, C. A., G. Pantaleo, and A. S. Fauci. 1995. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J. Immunol. 154:5555-5566.
262. Murphy, R. L., R. M. Gulick. V. DeGruttola, R. T. D'Aquila, J. J. Eron, J. P. Sommadossi, J. S. Currier, L. Smeaton, I. Frank, A. M. Caliendo, J. G. Gerber, R. Tung, and D. R. Kuritzkes. 1999. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J. Infect. Dis. 179:808-816.
263. Musey, L., J. Hughes, T. Schacker, T. Shea, L. Corey, and M. J. McElrath. 1997. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337:1267-1274.
264. Myers, G., S. Wain-Hobson, L. Henderson, B. Korber, K. Jeang, and G. Pavlakis. 1995. Human retroviruses and AIDS. Sequence bank. Los Alamos National Laboratory, Los Alamos, N.M.
265. Nabel, G. J. 1993. The role of cellular transcription factors in the regulation of human immunodeficiency virus gene expression, p. 49-73. In B. R. Cullen (ed.), Human retroviruses. IRL Press, Oxford, United Kingdom.
266. Naglik, J. R., G. Newport, T. C. White, L. L. Fernandez-Naglik, J. S. Greenspan, D. Greenspan, S. P. Sweet, S. J. Challaconbe, and N. Agabian. 1999. In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. Infect. Immun. 67:2482-2490.
267. Nagy, K., M. Young, C. Baboonian, J. Merson, P. Whittle, and S. Oroszlan. 1994. Antiviral effect of human immunodeficiency virus protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase. J. Virol. 68:757-765.
268. Najera, I., A. Holguin, M. E. Quinones-Mateu, M. A. Munoz-Fernandez, R. Najera, C. Lopez-Galindez, and E. Domingo. 1995. pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69:23-31.
269. Nakaya, T., K. Fujinaga, M. Kishi, S. Oka, T. Kurata, I. M. Jones, and K. Ikuta. 1994. Nonsense mutations in the vpr gene of HIV-1 during in vitro virus passage and in HIV-1 carrier-derived peripheral blood mononuclear cells. FEBS Lett. 354:17-22.
270. Nakaya, T., K. Fujinaga, H. Doi, S. Suzuki, H. Takahashi, Y. Nishino, M. Kishi, I. Azuma, R. B. Luftig, and K. Ikuta. 1996. Serial passage of human immunodeficiency virus type 1 generates misalignment deletions in non-essential accessory genes. Virus Res. 46:139-147.
271. Nakaya, T., S. Iwai, K. Fujinaga, Y. Sato, E. Otsuka, and K. Ikuta. 1997. Decoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev protein. Antimicrob. Agents Chemother. 41:319-325.
272. Niedecken, H., G. Lutz, R. Bauer, and H. W. Kreysel. 1987. Langerhans cell as primary target and vehicle for transmission of HIV. Lancet ii:519-520.
273. Nijhuis, M., R. Schuurman, and C. A. B. Boucher. 1997. Homologous recombination for rapid phenotyping of HIV. Curr. Opin. Infect. Dis. 10:475-479.
274. Nishino, Y., M. Kishi, M. Sumiya, K. Ogawa, A. Adachi, K. Maotani-Imai, S. Kato, K. Hirai, and K. Ikuta. 1991. Human immunodeficiency virus type 1 vif, vpr, and vpu mutants can produce persistently infected cells. Arch. Virol. 120:181-192.
275. Nishino, Y., T. Nakaya, K. Fujinaga, M. Kishi, I. Azuma, and K. Ikuta. 1994. Persistent infection of MT-4 cells by human immunodeficiency virus type 1 becomes increasingly likely with in vitro serial passage of wild-type but not nef mutant virus. J. Gen. Virol. 75:2241-2251.
276. Oberlin, E., A. Amara, F. Bachelerie, C. Bessia, J.-L. Virelizier, F. Arenzana-Seisdedos, O. Schwartz, J.-M. Heard, I. Clark-Lewis, D. F. Legler, M. Loetscher, M. Baggiolini, and B. Moser. 1996. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line adapted HIV-1. Nature 382:833-835.
277. + lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med. 334:426-431.
278. Ogawa, K., R. Shibata, T. Kiyomasu, I. Higuchi, Y. Kishida, A. Ishimoto, and A. Adachi. 1989. Mutational analysis of the human immunodeficiency virus vpr open reading frame. J. Virol. 63:4110-4114.
279. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon, and A. J. McMichael. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106.
280. Ohki, K., M. Kishi, Y. Nishino, M. Sumiya, T. Kimura, T. Goto, M. Nakai, and K. Ikuta. 1991. Noninfectious doughnut-shaped human immunodeficiency virus type 1 can induce syncytia mediated by fusion of the particles with CD4-positive cells. J. Acquir. Immune Defic. Syndr. 4:1233-1240.
281. Oldstone, M. B. 1997. HIV versus cytotoxic T lymphocytes - the war being lost. N. Engl. J. Med. 337:1306-1308.
282. Olivares, I., V. Sánchez-Merino, M. A. Martinez, E. Domingo, C. López-Galindez, and L. Menéndez-Arias. 1999. Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. J. Virol. 73:6293-6298.
283. Oroszlan, S., and R. B. Luftig. 1990. Retroviral proteinases, p. 153-186. In R. Swanstrom and P. K. Vogt (ed.), Retroviruses: strategies of replication. Springer-Verlag, New York, N.Y.
284. + T cells. J. Immunol. 153:5826-5837.
285. Owman, C., A. Garzino-Demo, F. Cocchi, M. Popovic, A. Sabirsh, and R. C. Gallo. 1998. The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. Proc. Natl. Acad. Sci. USA 95:9530-9534.
286. Oyaizu, N., T. W. McCloskey, M. Coronesi, N. Chirmule, and S. Pahwa. 1993. Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood 82:3075-3080.
287. Pandori, M. W., N. J. S. Fitch, H. M. Craig, D. D. Richman, C. A. Spina, and J. C. Guatelli. 1996. Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J. Virol. 70:4283-4290.
288. Pantaleo, G., and A. S. Fauci. 1995. New concepts in the immunopathogenesis of HIV infection. Annu. Rev. Immunol. 13:487-512.
289. + T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370:463-467.
290. Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358.
291. Partaledis, J., K. Yamaguchi, M. Tisdale, E. Blair, C. Falcione, B. Maschera, R. Myers, S. Pazhanisamy, O. Futer, A. Cullinan, C. Stuver, R. Byrn, and D. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylaminosulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
292. Patick, A., R. Rose, J. Greytok, C. Bechtold, M. Hermsmeier, P. Chen, J. Barrish, R. Zahler, R. Colonno, and P. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
293. Patterson, B. K., M. Till, P. Otto, C. Goolsby, M. R. Furtado, L. J. McBride, and S. M. Wolinsky. 1993. Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry. Science 260:976-979.
294. Pearl, L. H., and W. R. Taylor. 1987. A structural model for the retroviral proteases. Nature 329:351-354.
295. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
296. Perelson, A. S., P. Essunger, Y. Cao, M. Vasenen, A. Hurley, K. Saksela, M. Markowitz, and D. D. Ho. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191.
297. ++ mobilization following CD3 stimulation. J. Immunol. 147:3145-3148.
298. Pettit, S. C., R. Sanchez, T. Smith, R. Wehbie, D. Derse, and R. Swanstrom. 1998. HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells. AIDS Res. Hum. Retrovir. 14:1007-1014.
299. Pettoello-Mantovani, M., T. R. Kollmann, C. Raker, A. Kim, S. Yurasov, R. Tudor, H. Wiltshire, and H. Goldstein. 1997. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues. Antimicrob. Agents Chemother. 41:1880-1887.
300. Piatak, M., Jr., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K. C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
301. Pleskoff, O., C. Treboute, A. Brelot, N. Heveker, M. Seman, and M. Alizon. 1997. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 276:1874-1878.
302. Poeschla, E., and F. Wong-Staal. 1994. Antiviral and anticancer ribozymes Curr. Opin. Oncol. 6:601-606.
303. Pomerantz, R. J., D. Trono, M. B. Feinberg, and D. Baltimore. 1990. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 61:1271-1276.
304. Pomerantz, R. J., O. Bagasra, and D. Baltimore. 1992. Cellular latency of human immunodeficiency virus type 1. Curr. Opin. Immunol. 4:475-480.
305. Pope, M., G. H. Betjes, N. Romani, H. Hirmand, P. U. Cameron, L. Hoffman, S. Gezelter, G. Schuler, and R. M. Steinman. 1994. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection of HIV-1. Cell 78:389-398.
306. + T cells. J. Exp. Med. 182:2045-2056.
307. Pope, M., D. Elmore, D. Ho, and P. Marx. 1997. Dendritic cell-T cell mixtures, isolated from the skin and mucosa of macaques, support the replication of SIV. AIDS Res. Hum. Retrovir. 13:819-827.
308. Refaeli, Y., D. N. Levy, and D. B. Weiner. 1995. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc. Natl. Acad. Sci. USA 92:3621-3625.
309. Rey, O., J. Canon, and P. Krogstad. 1996. HIV-1 Gag protein associates with F-actin present in microfilaments. Virology 220:530-534.
310. Richards, A. D., R. Roberts, B. M. Dunn, M. C. Graves, and J. Kay. 1989. Selective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett. 247:113-117.
311. Richman, D. D., and S. A. Bozzette. 1994. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 169:968-974.
312. Ridky, T. W., A. Kikonyogo, J. Leis, S. Gulnik, T. Copeland, J. Erickson, A. Wlodawer, J. Kurinov, R. W. Harrison, and I. T. Weber. 1998. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Biochemistry 37:13835-13845.
313. Roberts, N. A. 1995. Drug-resistance patterns of saquinavir and other HIV protease inhibitors. AIDS 9:S27-S32.
314. Robinovitch, M. R., J. M. Iversen, and L. Resnick. 1993. Anti-infectivity activity of human salivary secretions toward human immunodeficiency virus. Crit. Rev. Oral Biol. Med. 4:455-459.
315. Rogel, M. E., L. I. Wu, and M. Emerman. 1995. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J. Virol. 69:882-888.
316. Rondon, I. J., and W. A. Marasco. 1997. Intracellular antibodies for gene therapy of infectious disease. Annu. Rev. Microbiol. 51:257-283.
317. Rose, R., Y. Gong, J. Greytok, C. Bechtold, B. Terry, B. Robinson, M. Alam, R. Colonno, and P. Lin. 1996. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93:1648-1653.
318. Rouzine, I. M., and J. M. Coffin. 1999. Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus. J. Virol. 73: 8167-8178.
319. Rowland-Jones, S, R. Tan, and A. McMichael. 1997. Role of cellular immunity in protection against HIV infection. Adv. Immunol. 65:277-346.
320. Rucker, J., A. L. Edinger, M. Sharron, M. Samson, B. Lee, J. F. Berson, Y. Yi, B. Margulies, R. G. Collman, B. J. Doranz, M. Parmentier, and R. W. Doms. 1997. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J. Virol. 71:8999-9007.
321. Sanchez, G., X. Xu, J.-C. Chermann, and I. Hirsch. 1997. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J. Virol. 71:2233-2240.
322. Sardana, V. V., A. J. Schlaback, P. Graham, B. L. Bush, J. H. Condra, J. C. Culberson, L. Gotlib, D. J. Graham, N. E. Kohl, R. L. LeFemina, C. L. Schneider, B. S. Wolanski, J. A. Wolanski, J. A. Wolfgang, and E. A. Emini. 1994. Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by ammo-acid substitutions in the enzyme substrate binding site. Biochemistry 33:2004-2010.
323. Sarmati, L., E. Nicastri, G. El-Sawaf, L. Ventura, A. Salanitro, L. Ercoli, S. Vella, and M. Andreoni. 1997. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment. J. Med. Virol. 53:313-318.
324. Schuitemaker, H., M. Koot, N. A. Kootstra, M. W. Dercksen, R. E. Y. De Goede, R. P. Van Steenwijk, J. M. A. Lange, J. K. M. Eeftink Schattenkerk. F. Miedema, and M. Tersmette. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66:1354-1360.
325. Sczakiel, G., and W. Nedbal. 1995. The potential of ribozymes as antiviral agents. Trends Microbiol. 3:213-217.
326. Shao, W. L. Everitt, M. Manchester, D. D. Loeb, C. A. Hutchison III, and R. Swanstrom. 1997. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc. Natl. Acad. Sci. USA 94:2243-2248.
327. Sheng, N., S. C. Pettit, R. J. Tritch, D. H. Ozturk, M. M. Rayner, R. Swanstrom, and S. Erickson-Vittanen. 1997. Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by protease. J. Virol. 71:5723-5732.
328. Shirasaka, T., S. Chokekijchai, A. Yamada, G. Gosselin, J.-L. Imbach, and H. Mitsuya. 1995. Comparative analysis of anti-human immunodeficiency virus type 1 activation of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 39: 2555-2559.
329. Shugars, D. C., and S. M. Wahl. 1998. The role of the oral environment in HIV-1 transmission J. Am. Dent. Assoc. 129:851-858.
330. Simmons, G., D. Wilkinson, J. D. Reeves, M. T. Dittmar, S. Beddows, J. Weber, G. Carnegie, U. Desselberger, P. W. Gray, R. A. Weiss, and P. R. Clapham. 1996. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either LESTR or CCR5 as coreceptors for virus entry. J. Virol. 70:8355-8360.
331. Singh, A., G. Besson, A. Mobasher, and R. O. Collman. 1999. Patterns of chemokine receptor fusion cofactor utilization by human immunodeficiency virus type 1 variants from the lungs and blood. J. Virol. 73:6680-6690.
332. Skalka, A. M. 1989. Retroviral proteases: first glimpses at the anatomy of a processing machine. Cell 56:911-913.
333. Soto-Ramirez, L. E., B. Renjifo, M. F. McLane, R. Marlink, C. O'Hara, R. Sutthent, C. Wasi, P. Vithayasai, V. Vithayasai, C. Apichartpiyakul, P. Auewarakul, V. P. Cruz, D.-S. Chui, R. Osathanondh, K. Mayer, T.-H. Lee, and M. Essex. 1996. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 271:1291-1293.
334. Spearman, P., R. Horton, L. Ratner, and I. Kuli-Zade. 1997. Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J. Virol. 71:6582-6592.
335. Spina, C. A., T. J. Kwoh, M. Y. Chowers, J. C. Guatelli, and D. D. Richman. 1994. The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J. Exp. Med. 179:115-123.
336. Spira, A. I., P. A. Marx, B. K. Patterson, J. Mahoney, R. A. Koup, S. M. Wolinsky, and D. D. Ho. 1996. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183:215-225.
337. St. Clair, M. H., P. M. Hartigan, J. C. Andrews, C. L. Vavro, M. S. Simberkoff, J. D. Hamilton, and Veterans Administration Cooperative Study Group. 1993. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease in a case-control study. J. Acquir. Immune Defic. Syndr. 6:891-897.
338. Stein, D. S., J. A. Korvick, and S. H. Vermund. 1992. CD4 lymphocyte cell enumeration for prediction of clinical course of HIV disease: a review. J. Infect. Dis. 165:352-363.
339. Strebel, K., D. Daugherty, D. Cohen, T. Folks, and M. A. Martin. 1987. The HIV "A" (sor) gene product is essential for virus infectivity. Nature 38:728-730.
340. Strebel, K., T. Klimkait, and M. A. Martin. 1988. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241:1221-1223.
341. Strebel, K., T. Klimkait, F. Maidarelli, and M. A. Martin. 1989. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J. Virol. 63:3784-3791.
342. Streblow, D. N., M. Kitabwalla, M. Malkowsky, and C. D. Pauza. 1998. Cyclophilin A modulates processing of HIV type I p55 Gag: mechanism for antiviral effects of cyclosporin A. Virology 245:197-202.
343. Streblow, D. N., M. Kitabwalla, and C. D. Pauza. 1998. Gag protein from human immunodeficiency virus type 1 assembles in the absence of cyclophilin A. Virology 252:228-234.
344. + T cells. Microbiol. Immunol. 44:111-121.
345. Tacchetti, C., A. Favre, L. Moresco, P. Meszaros, P. Luzzi, M. Truini, F. Rizzo, C. E. Grossi, and E. Ciccone. 1997. HIV is trapped and masked in the cytoplasm of lymph node follicular dendritic cells. Am. J. Pathol. 150: 533-542.
346. Temin, H. A. 1989. Is HIV unique or merely different? J. Acquir. Immun. Defic. Syndr. 2:1-9.
347. Tersmette, M., R. E. Y. De Goede, B. J. M. Al, I. N. Winkel, R. A. Gruters, H. T. M. Cuypers, H. G. Huisman, and F. Miedema. 1988. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J. Virol. 62:2026-2032.
348. Tersmette, M., R. A. Gruters, F. De Wolf, R. E. Y. De Goede, J. M. A. Lange, P. T. A. Schellekens, J. Goudsmit, J. G. Huisman, and F. Miedema. 1989. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J. Virol. 63:2118-2125.
349. Terwilliger, E. F. 1992. The accessory gene functions of the primate immunity viruses, p. 3-27. In W. C. Koff, F. Wong-Staal, and R. C. Kennedy (ed.), AIDS research reviews, vol. 2. Marcel Dekker, Inc., New York. N.Y.
350. Terwilliger, E. F., E. A. Cohen, Y. Lu, J. G. Sodrosky, and W. A. Haseltine. 1989. Functional role of human immunodeficiency virus type 1 vpu. Proc. Natl. Acad. Sci. USA 86:5163-5167.
351. Terwilliger, E. F., E. Langhoff, D. Gabuzda, E. Zazopoulos, and W. A. Haseltine. 1991. Allelic variation in the effects of the nef gene on replication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 88: 10971-10975.
352. Tobiume, M.. K. Fujinaga, M. Kameoka, T. Kimura, T. Nakaya, T. Yamada, and K. Ikuta. 1998. Dependence on host cell cycle for activation of human immunodeficiency virus type 1 gene expression from latency. J. Gen. Virol. 79:1363-1371.
353. Torres, Y., M. Leal, C. Rey, F. J. Medrano, A. Sanchez-Quijiano, and E. Lissen. 1996. Acquisition of syncytium-inducing HIV-1 strains during therapy with zidovudine alone or combined with alpha interferon or didanosine. Eur. J. Clin. Microbiol. Dis. 15:324-327.
354. Trkola, A., T. Dragic, J. Arthos, J. M. Binley, W. C. Olson, G. P. Allaway, C. Cheng-Mayer, J. Robinson, P. J. Maddon, and J. P. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature 384:184-187.
355. Van't Wout, A. B., H. Blaak, L. J. Ran, M. Brouwer, C. Kuiken, and H. Schuitemaker. 1998. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection. J. Virol. 72:5099-5107.
356. Van't Wout, A. B., M. D. De Jong, N. A. Kootstra, J. Veenstra, J. M. A. Lange, C. A. B. Boucher, and H. Schuitemaker. 1996. Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. J. Infect. Dis. 174:845-849.
357. Van't Wout, A. B., N. A. Kootstra, G. A. Mulder-Kampinga, N. Albrecht van Lent, H. J. Scherpbier, J. Veenstra, K. Boer, R. A. Coutinho, F. Miedema, and H. Schuitemaker. 1994. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parental and vertical transmission. J. Clin. Investig. 94:2060-2067.
358. Van't Wout, A. B., L. J. Ran, M. D. De Jong, M. Bakker, R. Van Leeuwen, D. W. Notemans, A. E. Loeliger, F. De Wolf, S. A. Danner, P. Reiss, C. A. B. Boucher, and J. M. A. Lange. 1997. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. J. Clin. Investig. 100:2325-2332.
359. von der Helm, K. 1977. Cleavage of Rous sarcoma viral polypeptide precursor into internal structural proteins in vitro involves viral protein p15. Proc. Natl. Acad. Sci. USA 74:911-915.
360. von Schwedler, U., R. S. Kornbluth, and D. Trono. 1994. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc. Natl. Acad. Sci. USA 91:6992-6996.
361. Wahl, S. M., T. B. McNeely, E. N. Janoff, D. Shugars, P. Worley, C. Tucker, and J. M. Orenstein. 1997. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Dis. 3(Suppl.):S64-S69.
362. Wahl, S. M., P. Worley, W. W. Jin, T. B. McNeely, S. Eisenberg, J. M. Orenstein, and E. Janoff. 1997. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissue. Am. J. Pathol. 150:1275-1284.
363. Wang, B., Y. C. Ge, P. Palasanthiran, S.-H. Xiang, J. Ziegler, D. E. Dwyer, C. Randle, D. Dowton, A. Cunningham, and N. K. Saksena. 1996. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pairs: in vivo evolution of vpr quasispecies in blood and plasma. Virology 223:224-232.
364. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Novak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-126.
365. Welker, R., H. Kottler, H. R. Kalbitzer, and H.-G. Kräusslich. 1996. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 219:228-236.
366. Westendrop, M. O., R. Frank, C. Ochsenbauer, K. Stricker, J. Dhein, H. Walczak, K.-M. Debatin, and P. H. Krammer. 1995. Sensitization of F cells to CD95-mediated apoptosis by HIV-1 tat and gp120. Nature 375:497-500.
367. Wilk, T., B. Gowen, and S. D. Fuller. 1999. Actin associates with the nucleocapsid domain of the human immunodeficiency virus Gag polyprotein. J. Virol. 73:1931-1946.
368. Winslow, D. L., S. Stack, P. King, H. Scarnati, A. Bincsik, and M. J. Otto. 1995. Limited sequence diversity in the HIV type 1 protease gene from clinical isolates and in vivo susceptibility to HIV protease inhibitors. AIDS Res. Hum. Retrovir. 11:107-113.
369. Wlodawer, A., and J. Vondrasek. 1998. Inhibitors of HlV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27:249-284.
370. Wlodawer, A., and J. W. Erickson. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:543-585.
371. + cells in human immunodeficiency virus type-1 infection. Clin. Immunol. Immunopathol. 63:126-134.
372. Yoshinaka, Y., and R. B. Luftig. 1977. Murine leukemia virus morphogenesis: cleavage of p70 in vitro can be accompanied by a shift from a concentrically coiled internal strand ("immature") to a collapsed ("mature") form of the virus core. Proc. Natl. Acad. Sci. USA 74:3446-3450.
373. Yu, M., M. C. Leavitt, M. Maruyama, O. Yamada, D. Young, A. D. Ho, and F. Wong-Staal. 1995. Intracellular immunization of human fetal cord blood stem/progenitor cells with a rihozyme against HIV-1. Proc. Natl. Acad. Sci. USA 92:699-703.
374. Yunoki, M., K. Maotani-Imai, H. Kusuda, M. Motoyama, S. Miyake, H. Imai, Y. S. Shin, S. Kato, K. Sano, C. Morita, M. Nakai, K. Hirai, and K. Ikuta. 1991. Production of infectious particles from defective human immunodeficiency virus type 1 (HIV-1)-producing cell clones by superinfection with infectious HIV-1. Arch. Virol. 116:143-158.
375. Zambruno, G., A. Giannetti, U. Bertazzoni, and G. Girolomoni. 1995. Langerhans cells and HIV infection. Immunol. Today 16:520-524.
376. Zhang, L., C. D. Carruthers, T. He, Y. Huang, Y. Cao, G. Wang, B. Hahn, and D. D. Ho. 1997. HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism. AIDS Res. Hum. Retrovir. 13:1357-1366.
377. Zhang, L., T. He, Y. Huang, Z. Chen, Y. Guo, S. Wu, K. J. Kunstman, R. C. Brown, J. P. Phair, A. U. Neumann, D. D. Ho, and S. M. Wolinsky. 1998. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J. Virol. 72:9307-9312.
378. Zhang, L., Y. Huang, T. He, Y. Cao, and D. D. Ho. 1996. HIV-1 subtype and second-receptor use. Nature 383:768.
379. Zhang, L., Y. Huang, H. Yuan, B. K. Chen, J. Ip, and D. D. Ho. 1997. Genetic and phenotypic characterization of long terminal repeat sequences from long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 71:5608-5613.
380. Zhang, L., Y. Huang, H. Yuan, S. Tuttleton, and D. D. Ho. 1997. Characterization of vif, vpr and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection. Virology 228:340-349.
381. Zhang, Y. J., T. Dragic, Y. Cao, L. Kostrikis, D. S. Kwon, D. R. Littman, V. N. Kewal-Ramani, and J. P. Moore. 1998. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 72:9337-9344.
382. Zhang, Y.-M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.
383. Zheng, N. N., P. W. McQueen, L. Hurren, L. A. Evans, M. G. Law, S. Forde, S. Barker, and D. A. Cooper. 1996. Changes in biologic phenotype of human immunodeficiency virus during treatment of patients with didanosine. J. Infect. Dis. 173:1092-1096.
384. + T-cells at nef rather than env V3 loci. Vaccine 15:497-510.
385. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup, and D. D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 261:1179-1181.
386. Ziermann, R., K. Limoli, K. Das, E. Arnold, C. J. Petropoulos, and N. T. Parkin. 2000. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J. Virol. 74: 4414-4419.